Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Chahua Modern Housewares Co Ltd
SSE:603615
|
CN |
|
Copenhagen Capital A/S
CSE:CPHCAP ST
|
DK |
|
Super Crop Safe Ltd
BSE:530883
|
IN |
|
C
|
China Sanjiang Fine Chemicals Co Ltd
HKEX:2198
|
CN |
|
Winmark Corp
NASDAQ:WINA
|
US |
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
US |
|
China Citic Bank Corp Ltd
SSE:601998
|
CN |
|
Atlas Global Brands Inc
OTC:AGBIF
|
CA |
|
Mayora Indah Tbk PT
IDX:MYOR
|
ID |
|
Amarjothi Spinning Mills Ltd
BSE:521097
|
IN |
|
MDJM Ltd
NASDAQ:UOKA
|
UK |
|
Q
|
QingCloud Technologies Corp
SSE:688316
|
CN |
Novan Inc
EPS (Diluted)
Novan Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
EPS (Diluted)
-$1
|
CAGR 3-Years
50%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$11
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$22
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's EPS (Diluted)?
EPS (Diluted)
-1.4
USD
Based on the financial report for Dec 31, 2022, Novan Inc's EPS (Diluted) amounts to -1.4 USD.
What is Novan Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
43%
Over the last year, the EPS (Diluted) growth was 18%. The average annual EPS (Diluted) growth rates for Novan Inc have been 50% over the past three years , 43% over the past five years .
